Details of the Drug
General Information of Drug (ID: DMA3FQP)
Drug Name |
6-(4-methylpiperazin-1-yl)-9Hpurine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
6-(4-methylpiperazin-1-yl)-9H-purine; 6-(4-methylpiperazin-1-yl)-7H-purine; CHEMBL594152; 99172-01-7; SDCCGMLS-0065440.P001; 6-(4-methylpiperazin-1-yl)-9Hpurine; AC1LFNRL; Oprea1_666011; MLS000419169; 6-(4-methylpiperazinyl)purine; SCHEMBL13718480; MolPort-000-847-583; MolPort-000-384-358; HMS2684L19; ZINC213869; HMS1650E09; CCG-26902; BBL036787; STK630143; BDBM50304512; NSC510935; AKOS001427557; AKOS005562847; NSC-510935; MCULE-5386395090; SMR000319851; ST45178781; AB00588487-02; SR-01000104630; SR-01000104630-1; Z57745256
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 218.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||